Alzheimer's Enzyme Discovery Reduces Brain Plaques

Researchers at Indiana University have identified a new approach to treating Alzheimer's disease — one that works by removing rather than adding. Removing a specific enzyme from neurons substantially reduces amyloid plaques, the protein clumps that are a hallmark of the disease.

The discovery comes as the Alzheimer's treatment landscape is already shifting. Recent FDA approvals of Leqembi and Kisunla have established that removing amyloid can slow disease progression. The Indiana University finding suggests there may be multiple pathways to achieve this goal — potentially offering new options for patients who don't respond to existing therapies.

The enzyme in question, when present, appears to contribute to plaque formation. Removing it doesn't just prevent new plaques; it reduces existing ones. This suggests a disease-modifying effect rather than mere symptom management.

Key Facts

• Institution: Indiana University School of Medicine
• Discovery: Enzyme removal reduces amyloid plaques
• Context: Builds on recent FDA approvals of Leqembi and Kisunla
• Mechanism: Removing enzyme from neurons (not adding drugs)

Why This Matters

This represents significant progress in health & medicine. The implications extend beyond the immediate story, suggesting broader shifts in how we approach challenges in this field. For individuals and communities affected, these developments offer tangible hope and practical benefits that could reshape their futures.

What We Don't Know Yet

As with any emerging development, important questions remain unanswered. Long-term outcomes still need to be established, and the full scope of impact across different populations requires further study. We will continue to monitor this story as more information becomes available.

Published 2026-04-20 · Category: Health & Medicine